Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement 1 inhibitor is a regulator of the alternative complement pathway.

H Jiang1, E Wagner, H Zhang

  • 1Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.

The Journal of Experimental Medicine
|December 6, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual disorder: does expert clinical experience support the rationale for cariprazine use?

European review for medical and pharmacological sciences·2024
Same author

Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis.

The British journal of psychiatry : the journal of mental science·2023
Same author

Incidence of tick-borne spotted fever group Rickettsia species in rodents in two regions in Kazakhstan.

Scientific reports·2022
Same author

Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.

Translational psychiatry·2022
Same author

[Radiological and functional results in high-energy tibial plate fractures].

Acta ortopedica mexicana·2022
Same author

The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment.

Endocrine-related cancer·2021
Same journal

Both soluble and cell surface CD137 expressed by Foxp3+ CD4 T cells restrain autoimmune diabetes.

The Journal of experimental medicine·2026
Same journal

Regulation of solid tumors by the peripheral nervous system.

The Journal of experimental medicine·2026
Same journal

Friend or foe? IFNλ drives fibrosis.

The Journal of experimental medicine·2026
Same journal

BAd-looking or CHarming: The two faces of BACH2.

The Journal of experimental medicine·2026
Same journal

Bridging veins govern discrepancy of CSF efflux into dura mater in mice.

The Journal of experimental medicine·2026
Same journal

Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation.

The Journal of experimental medicine·2026
See all related articles

Complement 1 inhibitor (C1-INH) regulates the alternative complement pathway. This study shows C1-INH inhibits paroxysmal nocturnal hemoglobinuria (PNH) erythrocyte lysis by preventing factor B and C3 binding.

Area of Science:

  • Immunology
  • Complement System Biology

Background:

  • The alternative complement pathway is a crucial part of innate immunity.
  • Dysregulation of the alternative pathway is implicated in various diseases.
  • Complement 1 inhibitor (C1-INH) is a known regulator of the classical and lectin pathways.

Purpose of the Study:

  • To investigate the role of C1-INH as an inhibitor of the alternative complement pathway.
  • To elucidate the molecular mechanisms by which C1-INH regulates the alternative pathway.

Main Methods:

  • Assessing C1-INH's effect on paroxysmal nocturnal hemoglobinuria (PNH) erythrocyte lysis in human serum.
  • Measuring the binding of factors B and C3 to erythrocytes.
  • Investigating C1-INH interaction with C3b and cobra venom factor (CVF) using immobilized assays.

Related Experiment Videos

  • Analyzing the effect of C1-INH on factor D-mediated cleavage of factor B.
  • Evaluating alternative pathway lysis upon C1-INH removal from serum.

    • Main Results:

    • C1-INH prevented alternative pathway-induced lysis of PNH erythrocytes.
    • C1-INH inhibited the binding of factors B and C3 to erythrocytes.
    • C1-INH bound to C3b and CVF, preventing factor B interaction with these components.
    • C1-INH inhibited factor D-mediated cleavage of factor B and subsequent C3 cleavage.
    • Removal of C1-INH significantly increased alternative pathway lysis.

    Conclusions:

    • C1-INH acts as a physiological downregulator of the alternative complement pathway convertase.
    • C1-INH inhibits the alternative pathway by interfering with factor B binding to C3b.
    • These findings highlight C1-INH's potential therapeutic role in alternative pathway-mediated diseases.